Discounted Cash Flow (DCF) Analysis Unlevered

Pyxis Oncology, Inc. (PYXS)

$1.61

-0.04 (-2.42%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 1.61 | undervalue

Operating Data

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
Revenue (%)
EBITDA --------
EBITDA (%)
EBIT --------
EBIT (%)
Depreciation --------
Depreciation (%)

Balance Sheet Data

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash --------
Total Cash (%)
Account Receivables --------
Account Receivables (%)
Inventories --------
Inventories (%)
Accounts Payable --------
Accounts Payable (%)
Capital Expenditure --------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 1.61
Beta 0.000
Diluted Shares Outstanding 8.49
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt 5.00%
Risk-Free Rate
Market Risk Premium
Cost of Equity 3.532
Total Debt -
Total Equity 13.67
Total Capital 13.67
Debt Weighting 0.00
Equity Weighting 100.00
Wacc

Build Up Free Cash

Year
A/P
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
EBITDA --------
EBIT --------
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT --------
Depreciation --------
Accounts Receivable --------
Inventories --------
Accounts Payable --------
Capital Expenditure --1.48-0.54-----
UFCF --------
WACC
PV UFCF --------
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 3.53
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -274.74
Equity Value -
Shares Outstanding 8.49
Equity Value Per Share -